Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Dutasteride × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1

Interventions

Gemcitabine 20 pembrolizumab 14 Specimen Handling 14 Magnetic Resonance Spectroscopy 14 Cisplatin 13 enfortumab vedotin 7 Nivolumab 7 Carboplatin 6 Mitomycin 5 Docetaxel 5 Cystoscopy 5 Biopsy 5 avelumab 4 Transurethral Resection of Bladder 4 Radiation 4 Mitozytrex 4 Fluorouracil 4 erdafitinib 3 durvalumab 3 dehydroftorafur 3 cabozantinib 3 atezolizumab 3 Platinum 3 1,2-diaminocyclohexaneplatinum II citrate 3 tremelimumab 2 sapanisertib 2 sacituzumab govitecan 2 relatlimab 2 eribulin 2 Radiotherapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡